Aterian (ATER) $18M Asset Sale: Cash Distribution Setup with a Tariff-Refund CVR

♦ Key Takeaways

Aterian (ATER) is selling its entire e-commerce brand portfolio to Trademark Global for $18.0 million and plans to push the net proceeds to common shareholders as a cash distribution in Q3 2026, alongside a non-transferable Contingent Value Right (CVR) covering tariff refunds and remaining asset liquidations.
At $0.95 on April 30, 2026, the stock is trading in the lower-middle of my back-of-envelope per-share distribution range of roughly $0.83–$1.20, with the CVR essentially priced as a free option. The proxy filing in early May should sharpen these numbers materially.
The CVR is the most interesting wrinkle: a federal court invalidated several IEEPA tariff regimes Aterian paid duties under in 2025, and the company has explicitly stated no asset has been recognized for potential refunds. That refund pool is the upside.
The catch: David Lazar's $7.0 million preferred investment leaves him with roughly 95.13% of the post-deal company on a fully-diluted basis, the deal requires a stockholder vote by July 20, 2026, and the company's auditor has flagged substantial doubt about going concern.

The Deal

Aterian, Inc. (NASDAQ: ATER) is a small-cap consumer products company that owns a portfolio of e-commerce brands sold primarily through Amazon. On April 28, 2026, the company announced two simultaneous transactions that together amount to a wind-down and reverse-merger: an $18.0 million asset sale to Trademark Global and a $7.0 million preferred-stock investment from David Lazar.

The asset sale covers Aterian's entire operating portfolio — Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct — for $18.0 million in cash, subject to working capital and other adjustments. Trademark Global will onboard the majority of supporting employees. Excluded from the deal: cash, certain Amazon accounts, intellectual property, corporate records, tax assets, and any indebtedness — those stay with Aterian.

The Lazar piece is structured as two preferred tranches. The first $3.5 million Series AA tranche closed April 27, 2026; the $3.5 million Series AAA tranche closes simultaneously with the asset sale, contingent on stockholder approval. After both close, Lazar will hold approximately 95.13% of the company on a fully-diluted basis and will become CEO. Crucially, per the Form 8-K filed April 29, 2026, Lazar and his affiliates contractually waived rights to the asset sale proceeds and to the CVR — meaning existing common holders capture 100% of those distributions.

Why This Matters

This is not a tender offer or a clean buyout. It's structured as a corporate reset where existing holders get cashed out via a dividend rather than at the share register. That makes it closer to a partial liquidation than a merger arb, and it's worth a careful look at the current price.

ATER closed at $0.657 on April 27 — the last unaffected day. The announcement landed after the close, the stock surged 122% the next day, and printed a $2.19 intraday high in the days that followed before retracing to $0.95 as of April 30, 2026. The market got excited, then started pricing in deductions.

There are two distinct cash pools, and only one of them goes to existing common shareholders. The asset sale net proceeds will be distributed to common holders. The company's existing balance-sheet cash — $4.9 million of unrestricted cash as of December 31, 2025, almost certainly lower today after Q1 2026 burn — stays with the post-deal Lazar shell. Lazar's $7 million preferred is structurally there to capitalize that shell. So when modeling per-share distribution, only the asset sale waterfall counts.

The Per-Share Math

The deal mechanics published so far don't quantify the distribution, but the source data lets me build a rough range.

Item	Amount	Confidence
Asset sale gross proceeds	$18.0M	High — stated in 8-K
Less: MidCap debt retirement	~($3–4M)	Medium-high — $4.3M as of Dec 31, 2025; the company has been paying it down ~$2M/quarter
Less: transaction costs (advisor fees, legal, buyer expense reimbursement cap of $600K)	~($2–3M)	Medium — not disclosed; estimate based on typical $25M-deal advisory economics
Less: working capital adjustments + retained reserves for excluded liabilities	~($1–3M)	Low — direction unclear; could swing either way
Net distribution pool	~$9–13M
Per share (10.82 million shares outstanding as of March 12, 2026)	~$0.83–$1.20

The $1–3M deduction line for working capital adjustments and retained reserves is doing real work in that spread — direction unknown, and the proxy statement (expected in early May) is what tightens this as Aterian will have to disclose an estimated distribution range there. Until then, anyone modeling specific numbers is working from incomplete data.

At $0.95 today, you're paying in the lower-middle of that estimated distribution range — roughly 32% of the way through the base-case spread. If the distribution lands at the midpoint of about $1.02 and you wait the four-to-five months to Q3 2026, that's a 7% return before any contribution from the CVR. If it lands at $1.05, the return is 10.5% — annualized, roughly 25-30%. If it lands at $1.20 (the top of the base range), the return jumps to 26%. If it lands at $0.85 (near the bottom), you're down about 10% before the CVR provides any cushion. The cash distribution alone has positive expected value if proceeds clear the midpoint, with the CVR providing additional optionality on top.

The CVR — Where the Upside Lives

The CVR is more concrete than the headlines suggest. It covers two pools: tariff refunds dating from 2025 forward, and proceeds from the liquidation of any remaining excluded assets.

The tariff piece is the interesting one. From Aterian's FY2025 10-K filed March 23, 2026:

"On August 29, 2025, the U.S. Court of International Trade ruled... that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs. This ruling effectively invalidated several tariff regimes in effect during 2025 under which the Company paid significant duties. While this decision may entitle the Company to refunds for previously paid IEEPA tariffs, the timing and process for such refunds remain uncertain, and no asset has been recognized as of December 31, 2025."

That last clause matters. Aterian paid "significant duties" under IEEPA in 2025, the court invalidated the underlying authority, and the company's accountants did not capitalize the potential refund as an asset. With Aterian's 2025 direct net revenue down $31.6 million (32.4%) on tariff-driven price increases, the underlying tariff cost base in 2025 was meaningful — even partial refunds could translate to a real per-share contribution to the CVR. The company hasn't published a tariff dollar figure, so any specific number here is speculative.

The Section 122 baseline 10% tariff effective February 24, 2026 is similarly time-limited (150 days unless extended). If that structure is challenged the same way IEEPA was, additional refunds could feed the CVR pool. The CVR is non-transferable, so whatever it pays, you're holding it through whenever the customs adjudication completes — which could stretch for years.

Key Terms

Vote required by July 20, 2026. Approval items include the asset sale, common-stock issuance on conversion of Lazar's preferred, an authorized share increase from 500 million to 1 billion shares, election of four Lazar director designees, and a reverse stock split in a 1-for-2 to 1-for-99 range.
Lazar waived distribution rights. Asset sale proceeds and CVR distributions go entirely to existing common holders.
No financing condition on the asset sale. Trademark Global is funding from its own resources.
Closing condition with teeth: the company must achieve contribution margins of 87.5% or higher during specified measurement periods. A miss gives the buyer a walk right.
Termination fee: $1,080,000 in defined termination scenarios. Buyer expense reimbursement capped at $600,000.
Voting agreement locks up directors and officers in favor of the transaction. They represent a small fraction of the float.
Going concern flagged. Aterian's independent registered public accounting firm included an explanatory paragraph in its FY2025 audit report raising substantial doubt about the company's ability to continue as a going concern.

Timeline

December 8, 2025

Aterian's board announces a strategic alternatives review process.

April 27, 2026

First $3.5M Series AA preferred tranche closes. ATER closes at $0.657 (last unaffected price).

April 28, 2026

Asset sale and securities purchase agreements publicly announced. Stock surges 122%.

April 29, 2026

Form 8-K filed with full deal terms.

Early May 2026

Preliminary proxy expected. The proxy is when Aterian will disclose an estimated per-share distribution range.

By July 20, 2026

Special stockholder meeting deadline.

Q2 2026

Expected asset sale closing. Second preferred tranche closes simultaneously. Lazar becomes CEO.

Q3 2026

Net asset sale proceeds distributed to existing common holders along with the CVR.

Risks

Vote risk. Approval requires affirmative votes on multiple items (asset sale, authorized share increase, director election, reverse split). Insiders are locked up but represent a small fraction of the float, and ATER has a heavy retail base. A "no" on any item could derail the structure.
Contribution margin condition. The 87.5% threshold is a closing condition the buyer can fall back on. For a business in run-off mode burning through inventory, there is real risk of a margin miss before close.
Working capital adjustments. The "$18 million base, subject to adjustments" language is doing meaningful work in the price. Final cash to the company could come in materially below $18 million if working capital settles unfavorably.
Cash burn between signing and close. Aterian's stockholders' equity dropped from $22.6M (Sept 2025) to $15.2M (Dec 2025). Operating losses are eating real money. Any extended timeline shrinks the distribution pool dollar-for-dollar.
Going concern. The auditor's substantial-doubt language is not boilerplate. If the deal terminates, the downside scenario is genuinely ugly — Aterian had only $4.9 million of unrestricted cash and $0.2 million of credit facility availability as of December 31, 2025.
CVR is non-transferable and unquantified. Tariff refund timing depends on customs adjudication that can stretch for years. Don't assign a specific value here without conviction.
Residual stub is essentially worthless near-term. The 4.87% post-deal stake in a Lazar shell is a free option, not a base case.

The Bottom Line

This is a contingent cash distribution play, not a tender offer. At $0.95, you are paying in the lower-middle of the base-case distribution range, leaving positive expected return on the cash distribution alone if proceeds clear the midpoint, with the CVR providing additional optionality. The proxy filing in early May is the next material catalyst — that is when the per-share math gets real. Until then, the spread is real but the contingencies are real too.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete 8-K filing and consult your own advisors before making any decisions.

Filed May 15, 2026 | PREM14A (Preliminary Merger Proxy)

The proxy landed and our $0.83–$1.20 estimate was almost dead-on: Aterian’s board now pegs the per-share distribution at $0.85–$1.14, on a total Dividend pool of $10.6M–$14.2M. But the proxy adds three things the original post didn’t cover — how Lazar’s $7M preferred actually plugs into the distribution math, a reverse stock split of up to 1-for-99 on the same ballot, and named-executive severance totals north of $2.5M — and at $1.30 today, the stock is now trading above the high end of the company’s own range.

What Changed

Distribution range now official: $0.85–$1.14 per share. The board estimates the Dividend pool at $10.6M to $14.2M. That implies a share count of roughly 12.46M, slightly above the 10.82M figure used in the original post (the proxy includes options and other equity that vest at change of control). Premium versus the $0.654 April 27 unaffected close: 29.9% to 74.1%.
Lazar’s $7M is part of the distribution pool, not a separate ring-fenced bucket. The proxy is explicit: “the net amount expected to be available for distribution to stockholders [comes] as a result of the proceeds from the Asset Sale and the Investment Transaction.” In other words, the $7M Lazar preferred funds both go-forward operations and the cash flowing out to common holders. Without Lazar’s capital, the distribution would be materially smaller.
A.G.P. fees: ~$1.25M total. ~$760K contingent on the asset sale closing, ~$350K contingent on the preferred sale, plus a $350K fairness opinion fee already paid.
Named executive severance: $2.52M total cash and equity acceleration.
- Arturo Rodriguez (CEO): $962,500 cash ($673,750 change in control + $288,750 pro-rata bonus) + $548,526 equity acceleration + $26,635 medical/dental (12 months) = $1,537,661
- Joshua Feldman (CFO): $620,000 cash ($465,000 + $155,000) + $331,028 equity + $26,635 benefits = $977,663
- Only two NEOs receive change-in-control payments under the Severance Plan; Joseph Risico (former co-CEO) is no longer at the company.
Reverse stock split on the same ballot. Range of 1-for-2 to 1-for-99, board’s discretion. Aterian has been out of compliance with Nasdaq’s $1.00 minimum bid price; this is the cure.
Tail D&O insurance is required at or before closing. No dollar estimate disclosed.
Tax treatment clarified. Distribution governed by Section 301. The CVR will likely be treated as having “reasonably ascertainable fair market value” at distribution — meaning holders take the FMV into income at distribution and then recognize gain/loss as the CVR pays out.
Specified Liabilities reserve quantified. Up to $6.0M held back for ongoing/potential obligations, plus $1.0M for operating costs. These reserves can flow back into the CVR pool later if they don’t get drawn.

Updated Per-Share Net Cash Math

The proxy disclosed the bottom-line range but not a line-item bridge. Here’s the bridge from gross proceeds to net distribution, reconstructed from the proxy’s “Use of Proceeds” waterfall:

Item	Amount	Source
Asset Sale gross proceeds	$18.0M	APA base purchase price (subject to net working capital adjustment)
Lazar Investment Transaction (Series AA + AAA Preferred)	$7.0M	Securities Purchase Agreement; proxy includes in distribution pool
Additional Proceeds (inventory, receivables, tariff/anti-dumping refunds, escrow releases, 4th & Heart, real property, residual brands)	TBD	Flow into CVR pool; not yet quantified
Less: Collateralized indebtedness (MidCap)	~($2–3M)	Paid “first” under the SPA waterfall; not separately quantified in proxy
Less: A.G.P. advisory fees	($1.25M)	Proxy “Opinion of A.G.P.” disclosure
Less: Legal, accounting, tail D&O policy	TBD	Bundled under “legal, financial advisory and other costs”
Less: Cash severance to Rodriguez + Feldman	($1.58M)	Golden Parachute Compensation table
Less: Prorated annual employee bonuses	TBD	Use-of-Proceeds clause (ii)(A)
Less: Operating reserve	($1.0M)	Use-of-Proceeds clause (iii)(A) — fixed
Less: Specified Liabilities reserve (Additional Reserves)	up to ($6.0M)	Use-of-Proceeds clause (iii)(B) — cap, can be smaller
Net Dividend pool	$10.6M–$14.2M	Disclosed by board
÷ Implied shares (back-solved from disclosed range)	~12.46M	$10.6M / $0.85 = 12.47M; $14.2M / $1.14 = 12.46M
Per share	$0.85–$1.14	Board estimate

The spread between the low end and high end ($0.29 per share, or roughly $3.6M in aggregate) is driven almost entirely by how much of the $6.0M Specified Liabilities reserve actually gets drawn. If those claims come in light, holders end up closer to $1.14. If the company has to fund the full $6M of contingent obligations, the distribution lands near $0.85. The CVR captures any reserve releases later, but timing on that is open-ended.

The Lazar Investment Transaction

The original post characterized Lazar’s $7M preferred as capital for the post-deal shell. The proxy clarifies it’s more than that: the $7M is explicitly part of the proceeds pool feeding the Dividend to common holders. Mechanically, Lazar pays $2.00 per share of preferred (Series AA tranche $3.5M closed April 27; Series AAA tranche $3.5M closes with the asset sale), and each Series AA preferred share converts into 7.7 shares of Common Stock. Series AAA converts into up to 135.10 shares per preferred share. Combined, Lazar ends up at roughly 95% of the fully-diluted post-deal company — consistent with the original post — while the cash he injected helps fund the cash exit for the rest of the float.

The practical read for existing holders: Lazar is paying $7M to take control of a public shell that, post-distribution, will have $1M of operating reserves, up to $6M of held-back Specified Liabilities reserves, and the rump CVR machinery. He’s contractually waived participation in both the Dividend and the CVR. So the trade is structurally clean — he gets the listing and the shell, common holders get the cash.

Reverse Stock Split

Proposal 6 asks for board discretion to effect a reverse split at any ratio from 1-for-2 up to 1-for-99. The trigger is straightforward: ATER has not maintained Nasdaq’s $1.00 minimum bid price for the required ten consecutive business days, and the company received a deficiency notice. Without a cure, Nasdaq delists. With a delisting, the stub becomes meaningfully harder for Lazar to use.

For existing holders, the practical impact on the distribution is zero — the dividend is set in dollars and paid before the split takes effect on the residual stub. But the 1-for-99 ceiling is unusually wide, and the ratio chosen will determine whether odd-lot holders end up with cash-in-lieu of fractional shares. If you hold a small ATER position primarily for the distribution, the split is irrelevant. If you’re considering holding the stub for the CVR, the ratio will affect how many shares you end up with.

CVR Treatment Clarified

The proxy nails down the tax mechanics, and there’s a wrinkle worth flagging. The cash distribution and CVR together are governed by Section 301 of the Code. Aterian expects no 2026 earnings and profits, which means the distribution should be characterized first as a tax-free return of capital (reducing your basis), then as capital gain to the extent it exceeds basis — rather than as an ordinary dividend.

The wrinkle: the company “currently expects to treat the CVRs as having a reasonably ascertainable fair market value at the time of the distribution.” That means at the moment the CVR is distributed, you take its FMV into the same Section 301 calculation. As cash payments come through the CVR later, you recognize additional gain or loss against the FMV-set basis. Translation: there is a taxable event at the moment the CVR drops, even if no cash has been received yet. The company hasn’t pre-stated what FMV they’ll assign — expect that in the definitive proxy or a follow-on filing. Holders in taxable accounts should plan to consult a tax advisor; holders in IRAs are unaffected.

Updated Bottom Line

ATER closed at $1.30 on May 18, 2026. That’s above the high end of the company’s own disclosed distribution range. At the midpoint of $1.00 per share, a buyer at $1.30 is paying $0.30 over expected cash, betting the CVR makes up the gap.

Scenario	Per-share cash	Return vs. $1.30 entry	CVR required to break even
Bear (full $6M Specified Liabilities draw)	$0.85	−34.6%	$0.45/share
Base (mid-range)	$1.00	−23.1%	$0.30/share
Bull (light reserve draw)	$1.14	−12.3%	$0.16/share

The arithmetic has flipped since the original post. At $0.95, the stock was in the lower-middle of the estimated range with positive expected return on cash alone. At $1.30, every cash scenario is now a loss — the CVR has to do real work to make the position profitable. The $0.45/share break-even in the bear case translates to roughly $5.6M of CVR proceeds — achievable if the IEEPA tariff refunds materialize at scale, but not a free option anymore.

What to do depends on your view of the CVR. If you assigned the CVR a meaningful expected value when the cash was a free ride, the higher entry price doesn’t change your thesis — it just compresses the cushion. If you were in this for the cash distribution arithmetic, the trade has been priced out; the spread you bought is now the market’s spread to consume.

Updated Key Facts

Detail	Previous	Updated
Per-share distribution range	$0.83–$1.20 (estimate)	$0.85–$1.14 (board disclosure)
Total Dividend pool	~$9M–$13M (estimate)	$10.6M–$14.2M (board disclosure)
Implied share count for distribution	10.82M (March 12, 2026)	~12.46M (back-solved from disclosed range)
A.G.P. advisory fees	Not disclosed	~$1.25M total
NEO severance (cash + equity + benefits)	Not disclosed	$2,515,324 (Rodriguez $1.54M + Feldman $0.98M)
Specified Liabilities reserve cap	Not disclosed	$6.0M (plus $1.0M operating reserve)
Reverse stock split	Not in original analysis	1-for-2 to 1-for-99 range, board discretion
Tax treatment of distribution	Not detailed	Section 301; expected return of capital then capital gain (no 2026 E&P)
CVR tax treatment	Not detailed	FMV taxable at distribution; basis-tracked thereafter
Current stock price	$0.95 (April 30, 2026)	$1.30 (May 18, 2026) — above proxy range high

Source: Aterian PREM14A filed May 15, 2026. This analysis is for informational purposes only and does not constitute investment advice.